Detalles de la búsqueda
1.
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
Pediatr Diabetes;
23(2): 173-182, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779087
2.
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Pediatr Diabetes;
23(2): 183-193, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779103
3.
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Diabetes Obes Metab;
21(4): 781-790, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30393950
4.
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Diabetes Obes Metab;
20(9): 2220-2228, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29766635
5.
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Diabetes Obes Metab;
20(9): 2229-2237, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761615
6.
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Am J Kidney Dis;
61(4): 579-87, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23352379
7.
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Cardiovasc Diabetol;
12: 3, 2013 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23286208
8.
A course for clinical trial personnel in clinical study designs, randomization, allocation schedules, and interactive response systems.
Pharm Stat;
10(2): 175-82, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-20967893
9.
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
BMC Endocr Disord;
10: 7, 2010 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-20412573
10.
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
J Diabetes;
8(5): 701-11, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26625270
11.
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
J Diabetes Investig;
7(5): 727-36, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27181998
12.
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Drugs Aging;
32(6): 469-76, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26041585
13.
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine.
Diabetes Ther;
6(2): 127-42, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25820927
14.
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.
Drugs Aging;
31(3): 203-14, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24510656
15.
Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.
Diabetes Ther;
4(1): 119-45, 2013 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23700194
16.
Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
Endocr Pract;
19(5): 751-7, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23757615
17.
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Diabetes Care;
36(5): 1067-73, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23248197
18.
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
J Diabetes Complications;
27(2): 177-83, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23116881
19.
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
J Diabetes;
5(1): 68-79, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22742523
20.
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Diabetes Res Clin Pract;
93(1): e15-7, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21477878